OSE Immunotherapeutics and Boehringer Ingelheim Expand Collaboration for Novel Treatments

OSE Immunotherapeutics and Boehringer Ingelheim have announced an expansion of their partnership. The collaboration now includes new projects aimed at developing first-in-class treatments for cancer and cardio-renal-metabolic (CRM) diseases.

One project broadens the therapeutic evaluation of an existing asset, while another involves a new asset acquisition. The anti-SIRPα compounds BI 765063 and BI 770371 are now being developed for CRM diseases. A new preclinical program focuses on OSE’s cis-targeting anti-PD1/cytokine platform.

CRM diseases affect over one billion lives and cause 20 million deaths annually. Cancer accounts for nearly 10 million deaths, highlighting the urgent need for effective treatments. The new programs aim to address these critical health issues.

OSE Immunotherapeutics will receive EUR 13.5 million upfront and may receive an additional EUR 17.5 million. The collaboration reflects both companies' commitment to developing breakthrough therapies in high-unmet medical need areas.